Abstract
The phenotypic resistance of selected organisms to ciprofloxacin, levofloxacin, and trovafloxacin was defined as a MIC of > or =4 microg/ml. The dynamics of resistance were studied after single and sequential drug exposures: clinical isolates of methicillin-susceptible and methicillin-resistant Staphylococcus aureus (MSSA and MRSA), Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, and Pseudomonas aeruginosa were utilized. After a single 48-h exposure of a large inoculum to four times the initial MIC for the organism, the frequency of selection of resistant mutants of MSSA was greater for trovafloxacin than levofloxacin (P = 0.008); for E. cloacae, the frequency was highest for ciprofloxacin and lowest for levofloxacin and trovafloxacin; for S. marcescens, the frequency was highest for trovafloxacin and lowest for ciprofloxacin (P = 0.003). The results of serial passage experiments were analyzed both by the Kaplan-Meier product-limited method as well as by analysis of variance of mean inhibitory values. By both methods, MSSA and MRSA expressed mutants resistant to ciprofloxacin after fewer passages than were required for either levofloxacin or trovafloxacin. For the aerobic gram-negative bacilli, two general patterns emerged. Mutants resistant to trovafloxacin appeared sooner and reached higher mean MICs than did mutants resistant to levofloxacin or ciprofloxacin. Mutants resistant to ciprofloxacin appeared later and reached mean MICs lower than the MICs of the other two drugs studied. Even though individual strain variation occurred, the mean MICs were reproduced when the serial passage experiment was repeated using an identical panel of E. coli isolates. In summary, the dynamic selection of fluoroquinolone-resistant bacteria can be demonstrated in experiments that employ serial passage of bacteria in vitro.
MeSH Terms
Anti-Infective Agents/pharmacology
Ciprofloxacin/pharmacology
Drug Resistance, Microbial/physiology
Enterobacteriaceae/drug effects,genetics
Fluoroquinolones
Humans
Levofloxacin
Microbial Sensitivity Tests
Mutation
Naphthyridines/pharmacology
Ofloxacin/pharmacology
Phenotype
Pseudomonas aeruginosa/drug effects,genetics
Regression Analysis
Reproducibility of Results
Staphylococcus aureus/drug effects,genetics
Chemicals
Anti-Infective Agents
Fluoroquinolones
Naphthyridines
Ciprofloxacin
Levofloxacin
trovafloxacin
Ofloxacin
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Gilbert D N
Earle A. Chiles Research Institute, Providence Portland Medical Center, Portland, Oregon 97213, USA. dagilbert@providence.org
Kohlhepp S J
Slama K A
Grunkemeier G
Lewis G
Dworkin R J
Slaughter S E
Leggett J E
References (21)
21 references, click to expand
-
Emergence and dissemination of quinolone-resistant Escherichia coli in the community.
Antimicrob Agents Chemother. 1999 Nov;43(11):2736-41
PMID: 10543756
-
Ciprofloxacin-resistant Salmonella typhi and treatment failure.
Lancet. 1999 May 8;353(9164):1590-1
PMID: 10334265
-
In vitro activity of CI-934, a new quinolone, compared with that of other quinolones and other antimicrobial agents.
Antimicrob Agents Chemother. 1986 May;29(5):852-7
PMID: 3729343
-
Ciprofloxacin for eradication of methicillin-resistant Staphylococcus aureus colonization.
Am J Med. 1987 Apr 27;82(4A):215-9
PMID: 3555039
-
Widespread quinolone resistance among methicillin-resistant Staphylococcus aureus isolates in a general hospital.
Antimicrob Agents Chemother. 1989 Apr;33(4):593-4
PMID: 2729953
-
Emergence of ciprofloxacin resistance in nosocomial methicillin-resistant Staphylococcus aureus isolates. Resistance during ciprofloxacin plus rifampin therapy for methicillin-resistant S aureus colonization.
Arch Intern Med. 1990 Oct;150(10):2151-5
PMID: 2222100
-
Increasing resistance of Staphylococcus aureus to ciprofloxacin.
Antimicrob Agents Chemother. 1990 Sep;34(9):1862-3
PMID: 2285306
-
Quinolone resistance in Pseudomonas aeruginosa and Staphylococcus aureus. Development during therapy and clinical significance.
Infection. 1994;22 Suppl 2:S111-21
PMID: 7927829
-
In vitro activity of fluoroquinolones against gram-positive bacteria.
Drugs. 1995;49 Suppl 2:48-57
PMID: 8549407
-
Emergence of fluoroquinolone-resistant Escherichia coli in fecal flora of cancer patients receiving norfloxacin prophylaxis.
Antimicrob Agents Chemother. 1996 Feb;40(2):503-5
PMID: 8834911
-
Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus.
Antimicrob Agents Chemother. 1996 Aug;40(8):1881-8
PMID: 8843298
-
Quinolone-resistant Neisseria gonorrhoeae in Hong Kong.
Sex Transm Dis. 1996 Mar-Apr;23(2):103-8
PMID: 8919735
-
DNA gyrase, topoisomerase IV, and the 4-quinolones.
Microbiol Mol Biol Rev. 1997 Sep;61(3):377-92
PMID: 9293187
-
Trends in antibiotic resistance among diarrheal pathogens isolated in Thailand over 15 years.
Clin Infect Dis. 1998 Feb;26(2):341-5
PMID: 9502453
-
Levofloxacin selects fluoroquinolone-resistant methicillin-resistant Staphylococcus aureus less frequently than ciprofloxacin.
J Antimicrob Chemother. 1998 Feb;41(2):285-8
PMID: 9533474
-
Antibacterial activity of gatifloxacin (AM-1155, CG5501, BMS-206584), a newly developed fluoroquinolone, against sequentially acquired quinolone-resistant mutants and the norA transformant of Staphylococcus aureus.
Antimicrob Agents Chemother. 1998 Aug;42(8):1917-22
PMID: 9687384
-
Bacterial topoisomerases, anti-topoisomerases, and anti-topoisomerase resistance.
Clin Infect Dis. 1998 Aug;27 Suppl 1:S54-63
PMID: 9710672
-
Examination of methicillin-resistant and methicillin-susceptible Staphylococcus aureus mutants with low-level fluoroquinolone resistance.
Antimicrob Agents Chemother. 1998 Dec;42(12):3317-9
PMID: 9835538
-
The global epidemiology of resistance to ciprofloxacin and the changing nature of antibiotic resistance: a 10 year perspective.
J Antimicrob Chemother. 1999 Mar;43 Suppl A:31-40
PMID: 10225569
-
Quinolone-resistant Campylobacter jejuni infections in Minnesota, 1992-1998. Investigation Team.
N Engl J Med. 1999 May 20;340(20):1525-32
PMID: 10332013
-
Activity of moxifloxacin against pathogens with decreased susceptibility to ciprofloxacin.
J Antimicrob Chemother. 1999 Nov;44(5):621-7
PMID: 10552978